Organon & Co. (NYSE:OGN) Given “Neutral” Rating at BNP Paribas Exane

BNP Paribas Exane reissued their neutral rating on shares of Organon & Co. (NYSE:OGN) in a research note released on Wednesday,Benzinga reports. They currently have a $14.00 price target on the stock, up from their previous price target of $12.00.

Other research analysts also recently issued research reports about the company. Piper Sandler upgraded Organon & Co. from an “underweight” rating to a “neutral” rating and boosted their price target for the company from $5.00 to $14.00 in a report on Tuesday. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Finally, Barclays upped their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Four research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $11.40.

Organon & Co. Stock Up 0.1%

Shares of NYSE:OGN opened at $13.34 on Wednesday. Organon & Co. has a 1 year low of $5.69 and a 1 year high of $13.38. The company has a market cap of $3.50 billion, a PE ratio of 18.79, a P/E/G ratio of 1.22 and a beta of 0.67. The company has a debt-to-equity ratio of 11.47, a current ratio of 1.82 and a quick ratio of 1.23. The stock’s 50-day moving average is $7.57 and its 200 day moving average is $7.72.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.10). Organon & Co. had a net margin of 3.01% and a return on equity of 122.01%. The business had revenue of $1.51 billion for the quarter, compared to analysts’ expectations of $1.52 billion. During the same quarter in the prior year, the firm earned $0.90 EPS. The firm’s revenue for the quarter was down 5.3% on a year-over-year basis. Sell-side analysts anticipate that Organon & Co. will post 3.23 EPS for the current year.

Organon & Co. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Monday, February 23rd were issued a dividend of $0.02 per share. The ex-dividend date was Monday, February 23rd. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s dividend payout ratio is 11.27%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC grew its stake in shares of Organon & Co. by 105.2% in the 4th quarter. AQR Capital Management LLC now owns 8,570,958 shares of the company’s stock worth $61,282,000 after buying an additional 4,394,814 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Organon & Co. by 11.3% in the 3rd quarter. Vanguard Group Inc. now owns 35,928,403 shares of the company’s stock worth $383,715,000 after buying an additional 3,650,860 shares during the last quarter. UBS Group AG grew its stake in shares of Organon & Co. by 55.2% in the 4th quarter. UBS Group AG now owns 4,295,002 shares of the company’s stock worth $30,795,000 after buying an additional 1,527,492 shares during the last quarter. Private Management Group Inc. grew its stake in shares of Organon & Co. by 38.3% in the 4th quarter. Private Management Group Inc. now owns 4,347,073 shares of the company’s stock worth $31,169,000 after buying an additional 1,204,979 shares during the last quarter. Finally, Balyasny Asset Management L.P. grew its stake in shares of Organon & Co. by 102.1% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,240,149 shares of the company’s stock worth $23,925,000 after buying an additional 1,131,941 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Key Headlines Impacting Organon & Co.

Here are the key news stories impacting Organon & Co. this week:

• Positive Sentiment: Sun Pharma deal and cash consideration provide a clear floor (shareholders to receive $14.00 per share), lifting M&A bidders’ enthusiasm and pushing the stock to 52-week highs. Organon & Co. (OGN) Soars to 52-Week High on $11.75-Billion Sun Merger
• Positive Sentiment: Piper Sandler upgraded OGN from underweight to neutral and set a $14.00 price target, signaling dealer support for the transaction price and narrowing downside risk. Piper Sandler upgrade
• Neutral Sentiment: Organon canceled its Q1 earnings call because of the announced agreement with Sun Pharma — a procedural step reflecting the pending deal rather than new operational news. Organon Cancels First Quarter Earnings Call
• Neutral Sentiment: BNP Paribas Exane reaffirmed a neutral rating and raised its price target to $14.00 (up from $12.00), aligning the street around the deal price while stopping short of a buy endorsement. BNP Paribas Exane reaffirmation
• Negative Sentiment: Law firms (Kahn Swick & Foti and Halper Sadeh) have launched investigations into whether the $14.00 cash price and the sale process are fair to shareholders — these inquiries can lead to litigation, potential delays, or renegotiation. Organon & Co. Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Organon Co. – OGN
• Negative Sentiment: BNP Paribas Exane previously moved OGN from strong?buy to hold (coverage adjustment), signaling reduced enthusiasm from a formerly bullish analyst and potentially limiting further upside absent a competing bidder or higher offer. Analyst downgrade

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.